Sort by
Multi-omics Analysis of the Epigenetic Effects of Inflammation in Murine Type II Pneumocytes
Jenna Fernandez,
Qiyuan Han,
Andrew T. Rajczewski,
Thomas Kono,
Nicholas Alexander Weirath,
Alexander S. Lee,
Abdur Rahim,
Natalia Y. Tretyakova
Posted: 16 April 2025
Chronic Exposure of Renal Progenitor Cells (HRTPT) to As (III) Implicates Microfibril Associated Protein 5 (MFAP5) in the Activation of Carcinoembryonic Antigen Related Cell Adhesion Molecules (CEACAM 5 & 6)
Md Ehsanul Haque,
Donald Sens,
Scott Garrett
Posted: 02 April 2025
Pesticide Pollution Provokes Histopathological Alterations in Apis mellifera (Linnaeus, 1758) Drone Gonads
Stela Stoyanova,
Elenka Georgieva,
Vesela Yancheva,
Lazslo Antal,
Plamen Petrov,
Krisztian Nyeste,
Dora Samogyi,
Evgenyia Ivanova
Posted: 28 March 2025
Composites of Reduced Graphene Oxide Based on Silver Nanoparticles and Their Effect on Breast Cancer Stem Cells
Babu Vimalanathan,
Devasena Thiyagarajan,
Ruby Nirmala Mary,
Magesh Sachidanandam,
Savarimuthu Ignacimuthu,
Dhanavathy Gnanasampanthapandian,
Johnson Rajasingh,
Kanagaraj Palaniyandi
Posted: 28 March 2025
Diosgenin, a Toxic Steroidal Sapogenin Present in Urochloa spp. (Poaceae) from the Orinoco Region in Colombia
Gonzalo J Diaz,
Maria C. Lozano
Posted: 27 March 2025
Modified Natural Clinoptilolite Alleviates Cadmium-Induced Toxicity in Icr Albino Mice
Michaela Beltcheva,
Yana Tzvetanova,
Peter Ostoich,
Iliana Aleksieva,
Tsenka Chassovnikarova,
Liliya Tsvetanova,
Rusi Rusew
Posted: 26 March 2025
The Hidden Danger of Amphetamine-Type Stimulants (ATS) and Opioids on Male Reproduction Toxicity: A Narrative Review
SITI FATIMAH IBRAHIM,
Khairul Osman,
Mohd Farisyam Mat Ros,
Farida Zuraina Mohd Yusof,
Ahmad Azwan Amin Nordin
Posted: 20 March 2025
Transcriptomics-Based Toxicological Study of Nickel on Caenorhabditis elegans 7th
Yutao He,
Yunfei Long,
Jingwen Wang,
Shunqing Xu
Posted: 20 March 2025
Integrating Exposures Across the Lifespan: Early Life Exposure to Trichloroethylene as a Risk Factor for Parkinson’s Disease
Allie Smith,
Alison Bernstein,
Briana R. De Miranda
Posted: 18 March 2025
Machine Learning on Toxicogenomic Data Reveals a Strong Association Between the Induction of Drug-Metabolizing Enzymes and Centrilobular Hepatocyte Hypertrophy in Rats
Kazuki Ikoma,
Takuomi Hosaka,
Akira Ooka,
Ryota Shizu,
Kouichi Yoshinari
Posted: 17 March 2025
Phototoxicity and Photoprotection Study of Agro-Derived Lignins and Nanocellulose
Juliana Varela Cruz,
Adriana S. Maddaleno,
Julia Salles Gava,
Washington Luiz Esteves Magalhães,
Danielle Palma de Oliveira,
Leme Daniela Morais,
Montserrat Mitjans,
Maria Pilar Vinardell
Posted: 26 February 2025
The Toxicity of RNA Polymerase Inhibitors Opens the Door to New Drug Generation Modulating Longevity
Ahmed Mohamed Helaly,
Doaa Ghorab
There are many RNA polymerase inhibitors, such as rifampicin, which acts as an antituberculosis agent, and relatively new antiviral drugs, such as sofosbuvir. These drugs have a safe profile and strong efficacy in treating tuberculosis and hepatitis C infections. Studies have shown that high doses of these compounds promote cell longevity (prolonging life span) in humans. It is hypothesized that these drugs also affect human RNA polymerases at high doses. We predicted that such inhibition inhibits the RNA transcription machinery, which is considered a pacemaker of the biological clock. It is important to shift research to human RNA polymerase modulators to develop new versions of drugs treating diseases such as neurodegenerative disorders. Although there is no data about the crystal structure of the human RNA polymerase, the mammalian and even the bacterial structures look conserved. It is important to raise concerns about cancer risk from potential new drugs targeting RNA polymerase. However, adding adjuvant therapy, such as vascular endothelial growth factor inhibitors, to RNA polymerase inhibitors can be a wise strategy at the end of the tunnel. The speed of RNA polymerase elongation modulates longevity. Aging affects the transcription machinery, and transcription activity affects longevity, creating a loop.
There are many RNA polymerase inhibitors, such as rifampicin, which acts as an antituberculosis agent, and relatively new antiviral drugs, such as sofosbuvir. These drugs have a safe profile and strong efficacy in treating tuberculosis and hepatitis C infections. Studies have shown that high doses of these compounds promote cell longevity (prolonging life span) in humans. It is hypothesized that these drugs also affect human RNA polymerases at high doses. We predicted that such inhibition inhibits the RNA transcription machinery, which is considered a pacemaker of the biological clock. It is important to shift research to human RNA polymerase modulators to develop new versions of drugs treating diseases such as neurodegenerative disorders. Although there is no data about the crystal structure of the human RNA polymerase, the mammalian and even the bacterial structures look conserved. It is important to raise concerns about cancer risk from potential new drugs targeting RNA polymerase. However, adding adjuvant therapy, such as vascular endothelial growth factor inhibitors, to RNA polymerase inhibitors can be a wise strategy at the end of the tunnel. The speed of RNA polymerase elongation modulates longevity. Aging affects the transcription machinery, and transcription activity affects longevity, creating a loop.
Posted: 19 February 2025
Concerning Mercury (Hg) Levels in the Hair of Children Inhabiting a Volcanically Active Area
Rute Fontes,
Nádia M. P. Coelho,
Patrícia Garcia,
Armindo S Rodrigues
Posted: 27 January 2025
Subject-Specific Mapping of Excess Manganese Accumulation in the Brain of Welders Using MRI Relaxometry
Humberto Monsivais,
Ulrike Dydak
In this work we demonstrate a novel methodology for personalized diagnosis and spatial characterization of abnormal Magnetic Resonance Imaging R1 (R1 = 1/T1) relaxation rates arising from excessive manganese (Mn) accumulation in welders’ brains. Utilizing voxel-wise population-derived norms based on a frequency age-matched non-exposed group (n = 25), we demonstrate the ability to conduct subject-specific assessments and mapping of Mn exposure using MRI relaxometry. Our results show elevated R1 in multiple brain regions in individual welders, but also extreme between-subject variability in Mn accumulation, debasing the concept that high exposures correlate with uniformly high Mn deposition in the brain. Consequently, the presented personalized methodology serves as a counterpart to group-based comparison, which allows for understanding the level of individual exposure and the toxicokinetics of Mn accumulation. This work lays a foundation for improved occupational health assessments and preventive measures against neurotoxic metal exposure.
In this work we demonstrate a novel methodology for personalized diagnosis and spatial characterization of abnormal Magnetic Resonance Imaging R1 (R1 = 1/T1) relaxation rates arising from excessive manganese (Mn) accumulation in welders’ brains. Utilizing voxel-wise population-derived norms based on a frequency age-matched non-exposed group (n = 25), we demonstrate the ability to conduct subject-specific assessments and mapping of Mn exposure using MRI relaxometry. Our results show elevated R1 in multiple brain regions in individual welders, but also extreme between-subject variability in Mn accumulation, debasing the concept that high exposures correlate with uniformly high Mn deposition in the brain. Consequently, the presented personalized methodology serves as a counterpart to group-based comparison, which allows for understanding the level of individual exposure and the toxicokinetics of Mn accumulation. This work lays a foundation for improved occupational health assessments and preventive measures against neurotoxic metal exposure.
Posted: 22 January 2025
From Traditional Amazon Use to Food Applications: Tapirira guianensis Seed Extracts as a Triad of Antiproliferative Effect, Oxidative Defense, and Antimalarial Activity
Marcell Crispim,
Thaise Caputo Silva,
Amanda dos Santos Lima,
Laura Da Silva Cruz,
Nathalia Alves Bento,
Thiago Mendanha Cruz,
Yasmin Stelle,
Josiana Moreira Mar,
Daniel de Queiroz Rocha,
Jaqueline de Araújo Bezerra
Posted: 14 January 2025
Bioaccumulation of Metals in Fish Collected from Macapá Urban Aquatic Environments (Brazilian Amazon) and the Risks to Human Health
Debora Cristina Damasceno de Souza,
Lucilene Finoto Viana,
Fábio Kummrow,
Claudia Andréa Lima Cardoso,
Nathalya Alice de Lima,
Bruno do Amaral Crispim,
Izabelle Alexandra Rodrigues Lacerda,
Alexeia Barufatti,
Lúcio André Viana Dias,
Alexandro Cezar Florentino
The city of Macapá in the Brazilian Amazon faces critical aquatic pollution challenges due to inadequate sanitation infrastructure, leading to heavy metal contamination in fish within its urban water bodies. This study evaluates concentrations of metals (Cu, Cd, Cr, Fe, Mn, Ni, Pb, Zn, Hg) in muscle tissues of fish from igarapés, floodplain lakes, and canals. Samples were collected from six sites to investigate the bioaccumulation of these metals and their potential human health risks. Using Atomic Absorption Spectrometry and Inductively Coupled Plasma Optical Emission Spectrometry for Hg, metal levels were analyzed in three carnivorous and seven omnivorous fish species. Cd concentrations in several species exceeded safety thresholds for human consumption, while the estimated daily intake (EDI) of Hg also surpassed reference doses. Risk assessment combining the risk quotient (RQ) for individual metals and the risk index (RI) for metal mixtures indicated considerable health risks associated with consuming fish from these contaminated waters. These findings reveal concerning exposure to contaminants, underscoring the need for environmental management and ongoing monitoring to protect public health in vulnerable urban areas.
The city of Macapá in the Brazilian Amazon faces critical aquatic pollution challenges due to inadequate sanitation infrastructure, leading to heavy metal contamination in fish within its urban water bodies. This study evaluates concentrations of metals (Cu, Cd, Cr, Fe, Mn, Ni, Pb, Zn, Hg) in muscle tissues of fish from igarapés, floodplain lakes, and canals. Samples were collected from six sites to investigate the bioaccumulation of these metals and their potential human health risks. Using Atomic Absorption Spectrometry and Inductively Coupled Plasma Optical Emission Spectrometry for Hg, metal levels were analyzed in three carnivorous and seven omnivorous fish species. Cd concentrations in several species exceeded safety thresholds for human consumption, while the estimated daily intake (EDI) of Hg also surpassed reference doses. Risk assessment combining the risk quotient (RQ) for individual metals and the risk index (RI) for metal mixtures indicated considerable health risks associated with consuming fish from these contaminated waters. These findings reveal concerning exposure to contaminants, underscoring the need for environmental management and ongoing monitoring to protect public health in vulnerable urban areas.
Posted: 13 January 2025
A Novel Preclinical Model to Assess Intestinal Barrier Integrity Using Canine Enteroids and Colonoids
Megan P Corbett,
Vojtech Gabriel,
Vanessa Livania,
David Díaz-Regañón,
Abigail Ralston,
Christopher Zdyrski,
Dongjie Liu,
Sarah Minkler,
Sichao Mao,
Hannah Wickham
Posted: 08 January 2025
Innovative Decontamination Strategies for Ochratoxin-A: Addressing Food Toxicity, Occurrence, and Safety Challenges
Rahim Khan,
Farooq Anwar,
Farinazleen Mohamad Ghazali,
Nor Ainy Mahyudin,
Mohd Sabri Pak Dek,
Arshad Iqbal,
Rahman Qadir
Posted: 26 December 2024
May a Clinical Implementation of the United Immune System Concept Help Delay the Onset of Degenerative Proteinopathies?
Theodor-Nicolae Carp
Degenerative proteinopathies constitute a set of molecular diseases that are caused by the misfolding of specific proteins, leading them to change their biochemical configuration and become toxic for entire systems of organs. Such protein toxicity induces the lysing of an increasing number of proteins that have a biochemically ‘wild-type’ version, gradually and eventually leading to a complete shift in the ratio between such ‘wild-type’ and ‘altered’ versions of such proteins, which directly precedes the clinical onset of such diseases. Proteinopathies not only involve neurodegenerative illnesses, but also a disease that leads to a progressive rate of blindness. Sadly, all such impairments that are neurodegenerative in nature may only receive palliative treatment, given that they are caused by aggregated proteins that start damaging and destroying entire neuronal systems, which leads to impairments in the neuro-muscular and ultimately to the inability of the patients to perform vital functions, like breathing and deglutition. There is neither a cure, nor a definitive method in which the progression of the illness can be stopped at the present time. Consequently, all neurodegenerative diseases have mortality rates of 100% and clinical approaches aim to reduce the suffering of such patients. Nonetheless, there seems to be a glimmer of hope regarding future prophylactic approaches that could delay the onset of many types of proteinopathies. Namely, an immune application could support efforts of clinical suffering delay and attenuation in an unprecedented manner. At the same time, it is necessary to emphasise upon realistic scenarios, that it remains virtually impossible to delay the onset of proteinopathies to the point of the patient reaching the average number of years in life expectancy without experiencing clinical symptoms yet. Initially, clinicians developed and tested a nasal spray containing a substance known as protollin, which stimulates a restricted extent of adaptive lymphocyte recruitment and transport to the central nervous system areas affected by initial stages of protein aggregation, activating a substantial number of microglial cells and preventing the lysis of numerous astrocytes, which in turn start lysing a number of beta-amyloid protein aggregates together without inducing pathophysiology, given the stage in which the patients have not experienced any clinical manifestation of the neurodegenerative disease yet. In case of an unsuccessful attempt to bring protollin above the threshold levels of clinical safety and efficacy, an immunostimulatory and immunomodulatory substance containing a low concentration of a mixture of recombinant Type I & III Interferons, innate and adaptive lymphocytes, perhaps themselves priorly treated with such IFN glycoproteins, would probably remain a vital candidate for an effective, yet probably still restricted delay of onset of various proteinopathies that could be neurodegenerative and optically degenerative. An existent success rate of the clinical test allows the opening of a window of opportunity regarding an increased efficacy of such adaptive lymphocyte approach, by including recombinant Type I and Type III Interferons into such a nasal spray, which could also enter adaptive lymphocyte and further improve their structural integrity and their multi-lateral functionality. Moreover, a low dose of protollin, Type I Interferons and Type III Interferons could be inserted in combination into adaptive T-Lymphocytes to optimise their defence mechanisms and immune functions, potentially bringing a considerable immunising effect against microbial diseases like HIV-induced, retroviral AIDS. Such an approach could create a stable and wide “highway bridge” of connection between innate and adaptive immunity, aiming for the best version of an immune contribution toward a considerable delay of proteinopathy clinical onset. Overall, there may be a requirement for a bi-lateral update of immunological research covering therapeutics and vaccine development; an immune system based optimisation that builds a stable and wide bridge of connection more directly between pre-cytokine and post-cytokine immune activation, and overall between innate and adaptive immune departments; and a pathogen-based optimisation that either eliminates or partially activates genes suppressive of Type I and Type III Interferon-encoding genes, helping enliven the concept of “United Immune System” as well, though less directly than the immune system-based potential approach.
Degenerative proteinopathies constitute a set of molecular diseases that are caused by the misfolding of specific proteins, leading them to change their biochemical configuration and become toxic for entire systems of organs. Such protein toxicity induces the lysing of an increasing number of proteins that have a biochemically ‘wild-type’ version, gradually and eventually leading to a complete shift in the ratio between such ‘wild-type’ and ‘altered’ versions of such proteins, which directly precedes the clinical onset of such diseases. Proteinopathies not only involve neurodegenerative illnesses, but also a disease that leads to a progressive rate of blindness. Sadly, all such impairments that are neurodegenerative in nature may only receive palliative treatment, given that they are caused by aggregated proteins that start damaging and destroying entire neuronal systems, which leads to impairments in the neuro-muscular and ultimately to the inability of the patients to perform vital functions, like breathing and deglutition. There is neither a cure, nor a definitive method in which the progression of the illness can be stopped at the present time. Consequently, all neurodegenerative diseases have mortality rates of 100% and clinical approaches aim to reduce the suffering of such patients. Nonetheless, there seems to be a glimmer of hope regarding future prophylactic approaches that could delay the onset of many types of proteinopathies. Namely, an immune application could support efforts of clinical suffering delay and attenuation in an unprecedented manner. At the same time, it is necessary to emphasise upon realistic scenarios, that it remains virtually impossible to delay the onset of proteinopathies to the point of the patient reaching the average number of years in life expectancy without experiencing clinical symptoms yet. Initially, clinicians developed and tested a nasal spray containing a substance known as protollin, which stimulates a restricted extent of adaptive lymphocyte recruitment and transport to the central nervous system areas affected by initial stages of protein aggregation, activating a substantial number of microglial cells and preventing the lysis of numerous astrocytes, which in turn start lysing a number of beta-amyloid protein aggregates together without inducing pathophysiology, given the stage in which the patients have not experienced any clinical manifestation of the neurodegenerative disease yet. In case of an unsuccessful attempt to bring protollin above the threshold levels of clinical safety and efficacy, an immunostimulatory and immunomodulatory substance containing a low concentration of a mixture of recombinant Type I & III Interferons, innate and adaptive lymphocytes, perhaps themselves priorly treated with such IFN glycoproteins, would probably remain a vital candidate for an effective, yet probably still restricted delay of onset of various proteinopathies that could be neurodegenerative and optically degenerative. An existent success rate of the clinical test allows the opening of a window of opportunity regarding an increased efficacy of such adaptive lymphocyte approach, by including recombinant Type I and Type III Interferons into such a nasal spray, which could also enter adaptive lymphocyte and further improve their structural integrity and their multi-lateral functionality. Moreover, a low dose of protollin, Type I Interferons and Type III Interferons could be inserted in combination into adaptive T-Lymphocytes to optimise their defence mechanisms and immune functions, potentially bringing a considerable immunising effect against microbial diseases like HIV-induced, retroviral AIDS. Such an approach could create a stable and wide “highway bridge” of connection between innate and adaptive immunity, aiming for the best version of an immune contribution toward a considerable delay of proteinopathy clinical onset. Overall, there may be a requirement for a bi-lateral update of immunological research covering therapeutics and vaccine development; an immune system based optimisation that builds a stable and wide bridge of connection more directly between pre-cytokine and post-cytokine immune activation, and overall between innate and adaptive immune departments; and a pathogen-based optimisation that either eliminates or partially activates genes suppressive of Type I and Type III Interferon-encoding genes, helping enliven the concept of “United Immune System” as well, though less directly than the immune system-based potential approach.
Posted: 11 December 2024
Formation of Potentially Toxic Metabolites of Polycyclic Aromatic Compounds (PAHs) in Reactions Catalyzed by Human Metabolizing Enzymes
Slobodan Petar Rendic
Posted: 09 December 2024
of 7